Observational studyMedicina (Kaunas, Lithuania)2023
Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in
Hsiang-Lin Tsai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.